Stanford University/Stanford Cancer Institute, Department of Medicine (Oncology), Stanford, CA, USA.
Expert Opin Biol Ther. 2013 Jan;13(1):115-20. doi: 10.1517/14712598.2013.745847. Epub 2012 Dec 1.
Angiogenesis, the recruitment and growth of blood vessels, is a process central to the growth of solid tumors. One of the key mediators of angiogenesis is the vascular endothelial growth factor (VEGF) family of ligands. An antibody to VEGF-A, bevacizumab, has demonstrated a survival benefit in conjunction with platinum-based doublet chemotherapy in non-small-cell lung cancer (NSCLC). Aflibercept (VEGF Trap) is a recombinant VEGF receptor-antibody protein fusion with higher affinity for VEGF-A than bevacizumab, plus affinity for VEGF-B and placental growth factor (PlGF).
This article reviews recent clinical trials investigating the role of aflibercept in the treatment of lung cancer, both published in the literature and those for which preliminary data have been presented at major scientific meetings.
Aflibercept has proven Phase III efficacy in metastatic colorectal cancer, but in lung cancer, large clinical trials have not yielded positive results. There remains hope that identification of biomarkers of response will one day help select patients most likely to benefit from antiangiogenesis therapy.
血管生成，即血管的募集和生长，是实体瘤生长的关键过程。血管内皮生长因子（VEGF）配体家族是血管生成的关键介质之一。针对 VEGF-A 的抗体贝伐珠单抗联合铂类双联化疗已被证明可改善非小细胞肺癌（NSCLC）患者的生存。阿柏西普（VEGF 陷阱）是一种重组 VEGF 受体-抗体蛋白融合物，与贝伐珠单抗相比，对 VEGF-A 的亲和力更高，同时对 VEGF-B 和胎盘生长因子（PlGF）也有亲和力。
本文综述了最近关于阿柏西普在肺癌治疗中的作用的临床试验，这些试验既有已发表在文献中的，也有在重要科学会议上公布的初步数据。
阿柏西普在转移性结直肠癌中已被证明具有 III 期疗效，但在肺癌中，大型临床试验并未取得阳性结果。人们仍然希望有一天能够确定反应的生物标志物，以帮助选择最有可能从抗血管生成治疗中获益的患者。
